![](/img/cover-not-exists.png)
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
Pettitt, A R, Matutes, E, Oscier, DVolume:
20
Year:
2006
Language:
english
Pages:
5
DOI:
10.1038/sj.leu.2404265
File:
PDF, 96 KB
english, 2006